CA
VKTX icon

Continuum Advisory’s Viking Therapeutics VKTX Stock Holding History

Continuum Advisory’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13
Closed -$314 – 1541
2025
Q1 		$314 Hold
13
– – ﹤0.01% 1606
2024
Q4 		$523 Hold
13
– – ﹤0.01% 1724
2024
Q3 		$696 Buy
+13
New +$763 ﹤0.01% 1715

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Continuum Advisory's VKTX Position: Q2 2025 in Review

Continuum Advisory sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 13 shares — an estimated $314 sold.

Continuum Advisory first reported a position in VKTX in Q3 2024 and held it in 3 quarters. The position peaked at $696 in Q3 2024. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

  • Continuum Advisory reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 13 Viking Therapeutics shares in Q2 2025, an estimated $314.
  • Continuum Advisory first reported a position in Viking Therapeutics in Q3 2024 and held it in 3 quarters.
  • Continuum Advisory's Viking Therapeutics position peaked at $696 in Q3 2024.
  • 391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.